Equity

Commodity News

Gland Pharma's Pashamylaram unit completes USFDA inspection
(18-Jan-2025, 11:36 Hours IST)  
Gland Pharma announced that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Pashamylaram Facility at Hyderabad between 25 July, 2024 and 02 August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Powered by Commodity Insights

FOR GRIEVANCE MAIL TO invgrieviss@iseindia.com

BSE EQUITIES : INB011077733 | NSE F&O EQUITIES : INF231077737 | NSE CASH MARKET : INB231077737 | NSE CURRENCY DERIVATIVES : INE231077737 | MCX-SX : INE261077737

ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited], a wholly owned subsidiary of Inter-connected Stock Exchange of India Ltd. (ISE)

© 2013 ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited]. All rights reserved.

Designed, developed & powered by C-MOTS Infotech (ISO 9001:2008 certified)